Abstract
Huntington’s Disease (HD) is a devastating neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, for which no disease modifying therapies are currently available. Much of the recent research has focused on developing therapies to directly lower HTT expression, and while promising, these therapies have presented several challenges regarding administration and efficacy. Another promising therapeutic approach is the modulation of HTT post-translational modifications (PTMs) that are dysregulated in disease and have shown to play a key role in HTT toxicity. Among all PTMs, modulation of HTT phosphorylation has been proposed as an attractive therapeutic option due to the possibility of orally administering specific kinase effectors. One of the kinases described to participate in HTT phosphorylation is Protein Kinase CK2. CK2 has recently emerged as a target for the treatment of several neurological and psychiatric disorders, although its role in HD remains controversial. While pharmacological studies in vitro inhibiting CK2 resulted in reduced HTT phosphorylation and increased toxicity, genetic approaches in mouse models of HD have provided beneficial effects. In this review we discuss potential therapeutic approaches related to the manipulation of HTT-PTMs with special emphasis on the role of CK2 as a therapeutic target in HD.
Original language | English (US) |
---|---|
Article number | 1979 |
Journal | Biomedicines |
Volume | 10 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2022 |
Bibliographical note
Funding Information:This research was funded by the National Institutes of Health (NINDS) R01NS110694 and R21NS116260 to R.G.P.
Publisher Copyright:
© 2022 by the authors.
Keywords
- CK2
- HTT phosphorylation
- Huntington’s disease
- kinase inhibition
- post-translation modifications
PubMed: MeSH publication types
- Journal Article
- Review